ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 294,22
-0,94%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Coherus BioSciences Inc (CHRS)

  7. Coherus BioSciences Inc (CHRS) Actualités

CHRS Coherus BioSciences Inc

2,25
0,08 (3,69%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Coherus BioSciences Inc CHRS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,08 3,69% 2,25 06:00:01
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,20 2,19 2,3219 2,27 2,17
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/5/202422:30GLOBECoherus to Report First Quarter 2024 Financial Results on..
24/4/202416:02GLOBECoherus Announces Presentation at the 2024 American Society..
08/4/202414:30GLOBECoherus Presents Preclinical Data for CHS-1000, a Novel..
13/3/202421:01GLOBECoherus BioSciences Reports Fourth Quarter, Full Year 2023..
05/3/202422:01GLOBECoherus to Report Fourth Quarter and Full Year 2023..
04/3/202412:22EDGAR2Form 8-K - Current report
04/3/202407:00GLOBECoherus Completes Divestiture of Ophthalmology Franchise
23/2/202423:33GLOBECoherus BioSciences Announces New Employment Inducement..
22/2/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202423:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/2/202422:59EDGAR2Form 8-K - Current report
21/2/202414:30GLOBECoherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and..
05/2/202414:09EDGAR2Form 8-K - Current report
05/2/202414:00GLOBECoherus Amends Term Loan Agreement with Pharmakon Advisors,..
24/1/202402:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202414:01EDGAR2Form 8-K - Current report
22/1/202407:59DJNSandoz to Acquire Cimerli Business from Coherus for $170..
22/1/202407:15GLOBECoherus Announces Agreement to Divest Ophthalmology..
18/1/202422:05GLOBECoherus Presents Positive Phase 2 Clinical Data on..
10/1/202403:41EDGAR2Form 8-K - Current report
10/1/202403:39EDGAR2Form 8-K - Current report
10/1/202401:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202400:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202423:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202423:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202414:00PRNUSINOVIO and Coherus Announce Clinical Collaboration to..
03/1/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:00GLOBECoherus BioSciences Management to Present at the 42nd Annual..
02/1/202414:29GLOBECoherus Announces U.S. Launch of LOQTORZI™
27/12/202315:15APSAnother Biotech Massively Outperforming Broader Equities
27/12/202312:08IHMARKETNEWSWall Street Highlights: Apple Appeals Watch Ban, Tesla to..
26/12/202322:43DJNCoherus BioSciences Gets FDA OK for Udenyca Injector
26/12/202322:01GLOBECoherus Announces FDA Approval of UDENYCA ONBODY™, a Novel..
22/12/202323:00GLOBECoherus BioSciences Announces New Employment Inducement..
15/12/202322:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202322:13EDGAR2Form 8-K - Current report
11/12/202314:30GLOBECoherus Announces Updated NCCN Clinical Practice Guidelines..
07/12/202323:55GLOBECoherus BioSciences Announces CFO Transition Plans
07/12/202323:16EDGAR2Form 8-K - Current report
06/12/202310:00GLOBECoherus Presents Phase 1/2 Clinical Data on Casdozokitug, a..
28/11/202317:16GLOBECoherus and Junshi Biosciences Announce Publication of..
27/11/202322:03EDGAR2Form 8-K - Current report
13/11/202312:07EDGAR2Form 8-K/A - Current report: [Amend]
06/11/202322:35EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202322:31EDGAR2Form 8-K - Current report
06/11/202322:07GLOBECoherus BioSciences Reports Third Quarter 2023 Financial..
06/11/202312:07EDGAR2Form 8-K/A - Current report: [Amend]
03/11/202313:30GLOBECoherus Presents Data from Next-generation Immuno-oncology..
03/11/202301:00GLOBECoherus BioSciences to Participate at Upcoming November..

Dernières Valeurs Consultées

NASDAQ
CHRS
Coherus BioSciences
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés